PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Arbutus Biopharma Corporation (ABUS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINCA03879J1003
CUSIP03879J100
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$469.37M
EPS-$0.44
Revenue (TTM)$18.14M
Gross Profit (TTM)-$45.39M
EBITDA (TTM)-$76.63M
Year Range$1.69 - $3.15
Target Price$4.40
Short %3.17%
Short Ratio2.72

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ABUS

Arbutus Biopharma Corporation

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Arbutus Biopharma Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%150.00%200.00%250.00%OctoberNovemberDecember2024FebruaryMarch
-63.70%
231.94%
ABUS (Arbutus Biopharma Corporation)
Benchmark (^GSPC)

S&P 500

Returns By Period

Arbutus Biopharma Corporation had a return of 4.80% year-to-date (YTD) and -12.37% in the last 12 months. Over the past 10 years, Arbutus Biopharma Corporation had an annualized return of -20.23%, while the S&P 500 had an annualized return of 10.61%, indicating that Arbutus Biopharma Corporation did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date4.80%7.28%
1 month-9.66%2.23%
6 months28.43%14.98%
1 year-12.37%30.65%
5 years (annualized)-6.85%12.59%
10 years (annualized)-20.23%10.61%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-5.20%18.14%
2023-6.45%-0.00%-9.85%12.02%21.95%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for Arbutus Biopharma Corporation (ABUS) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ABUS
Arbutus Biopharma Corporation
-0.35
^GSPC
S&P 500
2.64

Sharpe Ratio

The current Arbutus Biopharma Corporation Sharpe ratio is -0.35. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00OctoberNovemberDecember2024FebruaryMarch
-0.35
2.64
ABUS (Arbutus Biopharma Corporation)
Benchmark (^GSPC)

Dividends

Dividend History


Arbutus Biopharma Corporation doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-91.53%
-1.12%
ABUS (Arbutus Biopharma Corporation)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Arbutus Biopharma Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Arbutus Biopharma Corporation was 97.19%, occurring on Oct 9, 2019. The portfolio has not yet recovered.

The current Arbutus Biopharma Corporation drawdown is 91.53%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-97.19%Mar 12, 20141405Oct 9, 2019
-86.6%Oct 10, 2007218Dec 12, 20081159Oct 7, 20131377
-31.5%Oct 8, 201346Dec 11, 201320Jan 13, 201466
-29.84%Jul 24, 200715Aug 16, 200723Oct 5, 200738
-18.01%Feb 26, 20144Mar 3, 20142Mar 5, 20146

Volatility

Volatility Chart

The current Arbutus Biopharma Corporation volatility is 6.51%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%14.00%OctoberNovemberDecember2024FebruaryMarch
6.51%
3.36%
ABUS (Arbutus Biopharma Corporation)
Benchmark (^GSPC)

Financials

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM2023202220212020
Revenue

Total Revenue

18.14M18.14M39.02M10.99M6.91M

Cost Of Revenue

1.40M1.40M1.43M1.75M47.48M

Gross Profit

16.74M16.74M37.59M9.24M-40.57M
Operating Expenses

Selling, General & Admin Expenses

22.48M22.48M17.83M17.14M14.72M

R&D Expenses

73.70M73.70M84.41M65.50M47.48M

Total Operating Expenses

96.02M94.77M102.24M82.64M64.18M
Income

Income Before Tax

-72.85M-72.85M-65.01M-76.25M-63.75M

Operating Income

-77.88M-78.03M-65.46M-73.52M-57.81M

EBIT

-77.42M-78.03M-65.46M-73.52M-57.81M

Earnings From Continuing Operations

-72.85M-75.47M-69.46M-76.25M-63.75M

Net Income

-71.97M-72.85M-69.46M-77.35M-65.21M

Income Tax Expense

-1.07M-1.004.44M1.10M1.47M

Interest Expense

367.00K459.00K1.73M2.86M4.01M

Other Non-Operating Income (Expenses)

4.37M5.18M444.00K-2.73M-5.94M

Extraordinary Items

0.000.000.000.000.00

Discontinued Operations

0.000.000.000.000.00

Effect Of Accounting Charges

0.000.000.000.000.00

Non Recurring

0.000.000.000.0064.00K

Minority Interest

0.000.000.000.000.00

Other Items

0.000.000.000.000.00
Values in USD except per share items